NO324946B1 - 3-(heteroarylacetamido)-2-okso-azetidin-1-sulfonsyre-derivater som antibakterielle midler, samt fremstilling og anvendelse derav og farmasoytisk preparat - Google Patents

3-(heteroarylacetamido)-2-okso-azetidin-1-sulfonsyre-derivater som antibakterielle midler, samt fremstilling og anvendelse derav og farmasoytisk preparat Download PDF

Info

Publication number: NO324946B1
Authority: NO; Norway
Prior art keywords: compound; formula; hydrogen; preparation; sulfonic acid
Prior art date: 2000-09-14

Application number

NO20031162A

Other languages

English (en)

Norwegian (no)

Other versions

NO20031162D0 (no

NO20031162L (no

Inventor

Charles Fiakpui

George Thomas

Rajeshwar Singh

Ronald George Micetich

Andhe V Narender Reddy

Samarendra Nath Maiti

Sameeh M Salama

Original Assignee

Basilea Pharmaceutica Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-09-14

Filing date

2003-03-13

Publication date

2008-01-07

2003-03-13 Application filed by Basilea Pharmaceutica Ag filed Critical Basilea Pharmaceutica Ag

2003-03-13 Publication of NO20031162D0 publication Critical patent/NO20031162D0/no

2003-03-13 Publication of NO20031162L publication Critical patent/NO20031162L/no

2008-01-07 Publication of NO324946B1 publication Critical patent/NO324946B1/no

Links

238000002360 preparation method Methods 0.000 title claims description 19
239000003242 anti bacterial agent Substances 0.000 title description 10
239000008194 pharmaceutical composition Substances 0.000 title description 2
208000015181 infectious disease Diseases 0.000 claims abstract description 8
230000003287 optical effect Effects 0.000 claims abstract description 7
150000001875 compounds Chemical class 0.000 claims description 53
125000001841 imino group Chemical group [H]N=* 0.000 claims description 27
239000001257 hydrogen Substances 0.000 claims description 13
229910052739 hydrogen Inorganic materials 0.000 claims description 13
159000000000 sodium salts Chemical class 0.000 claims description 13
125000004432 carbon atom Chemical group C* 0.000 claims description 10
229910052757 nitrogen Inorganic materials 0.000 claims description 9
NSRVGDULUQOEBX-UHFFFAOYSA-N 3-amino-2-oxoazetidine-1-sulfonic acid Chemical compound NC1CN(S(O)(=O)=O)C1=O NSRVGDULUQOEBX-UHFFFAOYSA-N 0.000 claims description 7
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 7
150000001768 cations Chemical class 0.000 claims description 7
238000006243 chemical reaction Methods 0.000 claims description 7
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 7
239000000829 suppository Substances 0.000 claims description 7
238000004519 manufacturing process Methods 0.000 claims description 6
241000589516 Pseudomonas Species 0.000 claims description 5
239000002253 acid Substances 0.000 claims description 5
125000005843 halogen group Chemical group 0.000 claims description 5
208000035143 Bacterial infection Diseases 0.000 claims description 4
208000022362 bacterial infectious disease Diseases 0.000 claims description 4
239000003814 drug Substances 0.000 claims description 4
125000004433 nitrogen atom Chemical group N* 0.000 claims description 4
125000006239 protecting group Chemical group 0.000 claims description 4
125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 3
125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 3
229910052783 alkali metal Inorganic materials 0.000 claims description 3
150000001340 alkali metals Chemical class 0.000 claims description 3
229910052799 carbon Inorganic materials 0.000 claims description 3
125000004122 cyclic group Chemical group 0.000 claims description 3
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 3
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
239000000825 pharmaceutical preparation Substances 0.000 claims description 3
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 2
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 2
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
125000002723 alicyclic group Chemical group 0.000 claims description 2
229910052784 alkaline earth metal Inorganic materials 0.000 claims description 2
150000001342 alkaline earth metals Chemical class 0.000 claims description 2
150000001413 amino acids Chemical class 0.000 claims description 2
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 2
229910052794 bromium Inorganic materials 0.000 claims description 2
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 2
239000000460 chlorine Substances 0.000 claims description 2
229910052801 chlorine Inorganic materials 0.000 claims description 2
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 2
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
239000003937 drug carrier Substances 0.000 claims description 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
229910052731 fluorine Inorganic materials 0.000 claims description 2
239000011737 fluorine Substances 0.000 claims description 2
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
238000000034 method Methods 0.000 claims description 2
150000007530 organic bases Chemical class 0.000 claims description 2
239000002504 physiological saline solution Substances 0.000 claims description 2
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
239000012530 fluid Substances 0.000 claims 1
229940093181 glucose injection Drugs 0.000 claims 1
150000002431 hydrogen Chemical class 0.000 claims 1
244000052616 bacterial pathogen Species 0.000 abstract description 3
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 30
239000000203 mixture Substances 0.000 description 30
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 18
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 17
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
239000007787 solid Substances 0.000 description 13
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
239000000725 suspension Substances 0.000 description 11
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
239000000243 solution Substances 0.000 description 10
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
239000012153 distilled water Substances 0.000 description 8
239000002904 solvent Substances 0.000 description 8
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 7
229940088710 antibiotic agent Drugs 0.000 description 7
239000007924 injection Substances 0.000 description 7
238000002347 injection Methods 0.000 description 7
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 7
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 6
239000011541 reaction mixture Substances 0.000 description 6
QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 5
239000004480 active ingredient Substances 0.000 description 5
239000002585 base Substances 0.000 description 5
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
WZPBZJONDBGPKJ-VEHQQRBSSA-N aztreonam Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-N 0.000 description 4
238000004440 column chromatography Methods 0.000 description 4
TVMUHOAONWHJBV-UHFFFAOYSA-N dehydroglycine Chemical compound OC(=O)C=N TVMUHOAONWHJBV-UHFFFAOYSA-N 0.000 description 4
239000000376 reactant Substances 0.000 description 4
238000010898 silica gel chromatography Methods 0.000 description 4
235000002639 sodium chloride Nutrition 0.000 description 4
GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
241000894006 Bacteria Species 0.000 description 3
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
206010034133 Pathogen resistance Diseases 0.000 description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
239000004599 antimicrobial Substances 0.000 description 3
239000003782 beta lactam antibiotic agent Substances 0.000 description 3
238000002512 chemotherapy Methods 0.000 description 3
FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 3
238000009472 formulation Methods 0.000 description 3
239000012528 membrane Substances 0.000 description 3
UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 3
150000002923 oximes Chemical group 0.000 description 3
230000035699 permeability Effects 0.000 description 3
239000000546 pharmaceutical excipient Substances 0.000 description 3
150000003839 salts Chemical class 0.000 description 3
125000004495 thiazol-4-yl group Chemical group S1C=NC(=C1)* 0.000 description 3
-1 β-lactam compounds Chemical class 0.000 description 3
HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 description 2
ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 2
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
KEGFZKKQEBALIJ-UHFFFAOYSA-N 3,4-dihydroxy-1h-pyridin-2-one Chemical group OC=1C=CNC(=O)C=1O KEGFZKKQEBALIJ-UHFFFAOYSA-N 0.000 description 2
VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
244000215068 Acacia senegal Species 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
229920000084 Gum arabic Polymers 0.000 description 2
OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
108700020474 Penicillin-Binding Proteins Proteins 0.000 description 2
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
235000010489 acacia gum Nutrition 0.000 description 2
239000000205 acacia gum Substances 0.000 description 2
239000000654 additive Substances 0.000 description 2
230000000844 anti-bacterial effect Effects 0.000 description 2
229960003644 aztreonam Drugs 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
239000002775 capsule Substances 0.000 description 2
230000008859 change Effects 0.000 description 2
239000003086 colorant Substances 0.000 description 2
239000012043 crude product Substances 0.000 description 2
238000010511 deprotection reaction Methods 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
229940079593 drug Drugs 0.000 description 2
ZKQFHRVKCYFVCN-UHFFFAOYSA-N ethoxyethane;hexane Chemical compound CCOCC.CCCCCC ZKQFHRVKCYFVCN-UHFFFAOYSA-N 0.000 description 2
FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 2
244000000059 gram-positive pathogen Species 0.000 description 2
239000008187 granular material Substances 0.000 description 2
238000005984 hydrogenation reaction Methods 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
239000007788 liquid Substances 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
244000005700 microbiome Species 0.000 description 2
229940041009 monobactams Drugs 0.000 description 2
239000012044 organic layer Substances 0.000 description 2
KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
229910052700 potassium Inorganic materials 0.000 description 2
239000011591 potassium Substances 0.000 description 2
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
239000000843 powder Substances 0.000 description 2
239000000047 product Substances 0.000 description 2
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
XSCHRSMBECNVNS-UHFFFAOYSA-N quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
239000011734 sodium Substances 0.000 description 2
238000003756 stirring Methods 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
239000003826 tablet Substances 0.000 description 2
LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
ISUIVWNWEDIHJD-HRFVKAFMSA-N (2s,3s)-3-azaniumyl-2-methyl-4-oxoazetidine-1-sulfonate Chemical compound C[C@H]1[C@H](N)C(=O)N1S(O)(=O)=O ISUIVWNWEDIHJD-HRFVKAFMSA-N 0.000 description 1
DHXYGTAPMNUQON-UHFFFAOYSA-N (3-amino-4-oxoazetidin-2-yl)methyl carbamate Chemical compound NC1C(COC(N)=O)NC1=O DHXYGTAPMNUQON-UHFFFAOYSA-N 0.000 description 1
ZGYDUUIKQDPPNK-UHFFFAOYSA-N 1,5-dibenzhydryloxy-2-(hydroxymethyl)pyridin-4-one Chemical compound C=1N(OC(C=2C=CC=CC=2)C=2C=CC=CC=2)C(CO)=CC(=O)C=1OC(C=1C=CC=CC=1)C1=CC=CC=C1 ZGYDUUIKQDPPNK-UHFFFAOYSA-N 0.000 description 1
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 1
NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
239000005995 Aluminium silicate Substances 0.000 description 1
WZPBZJONDBGPKJ-UHFFFAOYSA-N Antibiotic SQ 26917 Natural products O=C1N(S(O)(=O)=O)C(C)C1NC(=O)C(=NOC(C)(C)C(O)=O)C1=CSC(N)=N1 WZPBZJONDBGPKJ-UHFFFAOYSA-N 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
229930186147 Cephalosporin Natural products 0.000 description 1
241000588919 Citrobacter freundii Species 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
239000001856 Ethyl cellulose Substances 0.000 description 1
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
206010061598 Immunodeficiency Diseases 0.000 description 1
AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
239000004166 Lanolin Substances 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
241000588772 Morganella morganii Species 0.000 description 1
229910002651 NO3 Inorganic materials 0.000 description 1
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
239000004372 Polyvinyl alcohol Substances 0.000 description 1
241000589517 Pseudomonas aeruginosa Species 0.000 description 1
229920001800 Shellac Polymers 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
241000295644 Staphylococcaceae Species 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
230000004075 alteration Effects 0.000 description 1
235000012211 aluminium silicate Nutrition 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
239000003781 beta lactamase inhibitor Substances 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
229940126813 beta-lactamase inhibitor Drugs 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
239000012267 brine Substances 0.000 description 1
239000000872 buffer Substances 0.000 description 1
FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
229910000024 caesium carbonate Inorganic materials 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
235000010216 calcium carbonate Nutrition 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
229940041011 carbapenems Drugs 0.000 description 1
125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
UIMOJFJSJSIGLV-JNHMLNOCSA-N carumonam Chemical compound O=C1N(S(O)(=O)=O)[C@H](COC(=O)N)[C@@H]1NC(=O)C(=N/OCC(O)=O)\C1=CSC(N)=N1 UIMOJFJSJSIGLV-JNHMLNOCSA-N 0.000 description 1
229960000662 carumonam Drugs 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
229940124587 cephalosporin Drugs 0.000 description 1
150000001780 cephalosporins Chemical class 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
230000009849 deactivation Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
238000003113 dilution method Methods 0.000 description 1
125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
230000000694 effects Effects 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
DERLTVRRWCJVCP-UHFFFAOYSA-N ethene;ethyl acetate Chemical compound C=C.CCOC(C)=O DERLTVRRWCJVCP-UHFFFAOYSA-N 0.000 description 1
LTOHTVPCWUZTJY-UHFFFAOYSA-N ethoxyethane;ethyl acetate;hexane Chemical compound CCOCC.CCCCCC.CCOC(C)=O LTOHTVPCWUZTJY-UHFFFAOYSA-N 0.000 description 1
235000019325 ethyl cellulose Nutrition 0.000 description 1
229920001249 ethyl cellulose Polymers 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
239000008103 glucose Substances 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
244000000058 gram-negative pathogen Species 0.000 description 1
GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
229910052742 iron Inorganic materials 0.000 description 1
239000007951 isotonicity adjuster Substances 0.000 description 1
NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
239000008101 lactose Substances 0.000 description 1
235000019388 lanolin Nutrition 0.000 description 1
229940039717 lanolin Drugs 0.000 description 1
239000003589 local anesthetic agent Substances 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
125000000896 monocarboxylic acid group Chemical group 0.000 description 1
239000012452 mother liquor Substances 0.000 description 1
XTAZYLNFDRKIHJ-UHFFFAOYSA-N n,n-dioctyloctan-1-amine Chemical compound CCCCCCCCN(CCCCCCCC)CCCCCCCC XTAZYLNFDRKIHJ-UHFFFAOYSA-N 0.000 description 1
239000002547 new drug Substances 0.000 description 1
239000012299 nitrogen atmosphere Substances 0.000 description 1
KPADFPAILITQBG-UHFFFAOYSA-N non-4-ene Chemical compound CCCCC=CCCC KPADFPAILITQBG-UHFFFAOYSA-N 0.000 description 1
CIAOJLKEFVPKRX-UHFFFAOYSA-N octadecapotassium;fluoro(dioxido)borane Chemical compound [K+].[K+].[K+].[K+].[K+].[K+].[K+].[K+].[K+].[K+].[K+].[K+].[K+].[K+].[K+].[K+].[K+].[K+].[O-]B([O-])F.[O-]B([O-])F.[O-]B([O-])F.[O-]B([O-])F.[O-]B([O-])F.[O-]B([O-])F.[O-]B([O-])F.[O-]B([O-])F.[O-]B([O-])F CIAOJLKEFVPKRX-UHFFFAOYSA-N 0.000 description 1
244000039328 opportunistic pathogen Species 0.000 description 1
229960003104 ornithine Drugs 0.000 description 1
239000003002 pH adjusting agent Substances 0.000 description 1
229910052763 palladium Inorganic materials 0.000 description 1
150000002960 penicillins Chemical class 0.000 description 1
229910052697 platinum Inorganic materials 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
229920001289 polyvinyl ether Polymers 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
239000011736 potassium bicarbonate Substances 0.000 description 1
229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
235000015497 potassium bicarbonate Nutrition 0.000 description 1
229910000027 potassium carbonate Inorganic materials 0.000 description 1
235000011181 potassium carbonates Nutrition 0.000 description 1
TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
GGOZGYRTNQBSSA-UHFFFAOYSA-N pyridine-2,3-diol Chemical compound OC1=CC=CN=C1O GGOZGYRTNQBSSA-UHFFFAOYSA-N 0.000 description 1
230000035484 reaction time Effects 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
210000000664 rectum Anatomy 0.000 description 1
230000009467 reduction Effects 0.000 description 1
238000010992 reflux Methods 0.000 description 1
229910052703 rhodium Inorganic materials 0.000 description 1
239000004208 shellac Substances 0.000 description 1
235000013874 shellac Nutrition 0.000 description 1
229940113147 shellac Drugs 0.000 description 1
ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
235000010413 sodium alginate Nutrition 0.000 description 1
239000000661 sodium alginate Substances 0.000 description 1
229940005550 sodium alginate Drugs 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
235000017550 sodium carbonate Nutrition 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
229910052938 sodium sulfate Inorganic materials 0.000 description 1
235000011152 sodium sulphate Nutrition 0.000 description 1
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
239000011877 solvent mixture Substances 0.000 description 1
125000006850 spacer group Chemical group 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
UDYFLDICVHJSOY-UHFFFAOYSA-N sulfur trioxide-pyridine complex Substances O=S(=O)=O.C1=CC=NC=C1 UDYFLDICVHJSOY-UHFFFAOYSA-N 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
DZLFLBLQUQXARW-UHFFFAOYSA-N tetrabutylammonium Chemical class CCCC[N+](CCCC)(CCCC)CCCC DZLFLBLQUQXARW-UHFFFAOYSA-N 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical compound CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
239000002132 β-lactam antibiotic Substances 0.000 description 1
229940124586 β-lactam antibiotics Drugs 0.000 description 1
229940126085 β‑Lactamase Inhibitor Drugs 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Communicable Diseases (AREA)
Pharmacology & Pharmacy (AREA)
Oncology (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

NO20031162A 2000-09-14 2003-03-13 3-(heteroarylacetamido)-2-okso-azetidin-1-sulfonsyre-derivater som antibakterielle midler, samt fremstilling og anvendelse derav og farmasoytisk preparat NO324946B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US23261700P	2000-09-14	2000-09-14
PCT/IB2001/002115 WO2002022613A1 (en)	2000-09-14	2001-09-14	3-(heteroaryl acetamido)-2-oxo-azetidine-1-sulfonic acids derivatives as antibacterial agents

Publications (3)

Publication Number	Publication Date
NO20031162D0 NO20031162D0 (no)	2003-03-13
NO20031162L NO20031162L (no)	2003-03-13
NO324946B1 true NO324946B1 (no)	2008-01-07

Family

ID=22873854

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20031162A NO324946B1 (no)	2000-09-14	2003-03-13	3-(heteroarylacetamido)-2-okso-azetidin-1-sulfonsyre-derivater som antibakterielle midler, samt fremstilling og anvendelse derav og farmasoytisk preparat

Country Status (22)

Country	Link
US (1)	US6916803B2 (de)
EP (1)	EP1322648B1 (de)
JP (1)	JP2004509122A (de)
KR (1)	KR100854810B1 (de)
CN (1)	CN1189469C (de)
AT (1)	ATE298750T1 (de)
AU (2)	AU2002212614B2 (de)
BR (1)	BR0113861A (de)
CA (1)	CA2422375C (de)
CZ (1)	CZ304586B6 (de)
DE (1)	DE60111757T2 (de)
DK (1)	DK1322648T3 (de)
ES (1)	ES2244666T3 (de)
HU (1)	HUP0301025A3 (de)
IL (2)	IL154593A0 (de)
NO (1)	NO324946B1 (de)
NZ (1)	NZ524292A (de)
PL (1)	PL218196B1 (de)
PT (1)	PT1322648E (de)
SK (1)	SK2462003A3 (de)
WO (1)	WO2002022613A1 (de)
ZA (1)	ZA200302085B (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE529111T1 (de) *	2005-12-07	2011-11-15	Basilea Pharmaceutica Ag	Nützliche monobactam-antibiotika
AU2012233003B2 (en) *	2005-12-07	2014-12-18	Basilea Pharmaceutica Ag	Useful combinations of monobactam antibiotics with beta-lactamase inhibitors
KR101320718B1 (ko)	2007-03-23	2013-10-21	바실리어 파마슈티카 아게	세균 감염 치료용 조합 약제
WO2009114921A1 (en) *	2008-03-17	2009-09-24	Dmitrienko Gary I	INHIBITORS OF CLASS B AND CLASS D β-LACTAMASES
PL3412676T3 (pl)	2010-08-10	2021-04-06	Melinta Therapeutics, Inc.	Cykliczne pochodne estrowe kwasu boronowego, sposób otrzymywania oraz ich zastosowania terapeutyczne
WO2013033461A1 (en)	2011-08-31	2013-03-07	Rempex Pharmaceuticals, Inc.	Heterocyclic boronic acid ester derivatives and therapeutic uses thereof
UY34585A (es) *	2012-01-24	2013-09-02	Aicuris Gmbh & Co Kg	Compuestos b-lactámicos sustituidos con amidina, su preparación y uso
US9156858B2 (en)	2012-05-23	2015-10-13	Rempex Pharmaceuticals, Inc.	Boronic acid derivatives and therapeutic uses thereof
US10561675B2 (en)	2012-06-06	2020-02-18	Rempex Pharmaceuticals, Inc.	Cyclic boronic acid ester derivatives and therapeutic uses thereof
CN102757405B (zh) *	2012-07-25	2014-04-16	山东理工大学	含噻二唑的香兰素衍生物、其制备方法及其用途
KR20150103270A (ko)	2013-01-04	2015-09-09	렘펙스 파머수티클스 인코퍼레이티드	보론산 유도체 및 그의 치료적 용도
US9241947B2 (en)	2013-01-04	2016-01-26	Rempex Pharmaceuticals, Inc.	Boronic acid derivatives and therapeutic uses thereof
EP2941246A4 (de)	2013-01-04	2016-12-21	Rempex Pharmaceuticals Inc	Borsäurederivate und therapeutische verwendungen davon
US9101638B2 (en)	2013-01-04	2015-08-11	Rempex Pharmaceuticals, Inc.	Boronic acid derivatives and therapeutic uses thereof
EP3140310B1 (de)	2014-05-05	2019-08-07	Rempex Pharmaceuticals, Inc.	Synthese von boronatsalzen und verwendungen davon
US9687497B1 (en)	2014-05-05	2017-06-27	Rempex Pharmaceuticals, Inc.	Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof
AU2015264418A1 (en)	2014-05-19	2016-11-10	Rempex Pharmaceuticals, Inc.	Boronic acid derivatives and therapeutic uses thereof
US10206937B2 (en)	2014-07-01	2019-02-19	Qpex Biopharma, Inc.	Boronic acid derivatives and therapeutic uses thereof
WO2016081297A1 (en)	2014-11-18	2016-05-26	Rempex Pharmaceuticals, Inc.	Cyclic boronic acid ester derivatives and therapeutic uses thereof
US10364257B2 (en)	2014-12-19	2019-07-30	Rempex Pharmaceuticals, Inc.	Apparatus and continuous flow process for production of boronic acid derivatives
US20180051041A1 (en)	2015-03-17	2018-02-22	Rempex Pharmaceuticals, Inc.	Boronic acid derivatives and therapeutic uses thereof
MY196909A (en)	2016-06-30	2023-05-09	Qpex Biopharma Inc	Boronic acid derivatives and therapeutic uses thereof
CN107641119B (zh) *	2016-07-21	2019-11-08	中国科学院上海药物研究所	单环β-内酰胺-铁载体轭合物及其制备方法和用途
MX2019007613A (es)	2016-12-21	2019-09-04	Aicuris Gmbh & Co Kg	Terapia de combinacion con compuestos ?-lactamicos sustituidos con amidina e inhibidores de ?-lactamasa para infecciones con cepas bacterianas resistentes a antibioticos.
EP3694864B1 (de)	2017-10-11	2025-03-05	Qpex Biopharma, Inc.	Boronsäurederivate und ihre synthese
JP7280273B2 (ja)	2018-01-29	2023-05-23	メッドシャインディスカバリーインコーポレイテッド	細菌感染を治療するための単環β－ラクタム化合物
AU2019256351B2 (en)	2018-04-20	2024-02-29	Qpex Biopharma, Inc.	Boronic acid derivatives and therapeutic uses thereof
CN113227088B (zh)	2018-12-18	2022-05-31	南京明德新药研发有限公司	单环β-内酰胺化合物在制药中的应用
SI25892A (sl) *	2019-09-05	2021-03-31	Gorenje Gospodinjski Aparati, D.O.O.	Pralni stroj, ki se polni s sprednje strani, z električnim svetlobnim telesom
WO2021048613A2 (en) *	2019-09-11	2021-03-18	Tennor Therapeutics Limited	Penam derivatives for treating bacterial infections
EP4046998B1 (de)	2019-11-22	2024-02-28	Suzhou Erye Pharmaceutical Co., Ltd.	Sulfonylharnstoffring-substituierte monocyclische beta-lactam-antibiotika
CN114828850B (zh)	2019-12-19	2024-08-13	深圳嘉科生物科技有限公司	化合物在制药中的应用
US12552815B2 (en)	2020-05-05	2026-02-17	Qpex Biopharma, Inc.	Boronic acid derivatives and synthesis, polymorphic forms, and therapeutic uses thereof
CN113754651B (zh) *	2020-06-02	2023-04-18	中国医学科学院医药生物技术研究所	一种β-内酰胺化合物、其用途及其制备方法
MX2023011616A (es)	2021-03-31	2023-10-30	Fedora Pharmaceuticals Inc	Compuestos de lactivicina, su preparacion y uso como agentes antibacterianos.
JP2024532211A (ja) *	2021-08-20	2024-09-05	ユニバーシティ・オブ・ノートル・ダム・デュ・ラック	単環式β－ラクタムとシデロフォア模倣体との結合体
CN115304594B (zh)	2022-10-12	2023-02-14	苏州二叶制药有限公司	磺酰脲环取代的化合物的盐型及其晶型

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4632985A (en) *	1985-06-03	1986-12-30	E. R. Squibb & Sons, Inc.	3-acylamino-2-oxo-1-azetidinesulfonic acids
GB8810396D0 (en) *	1988-05-03	1988-06-08	Glaxo Group Ltd	Chemical process
US5112968A (en) *	1989-07-28	1992-05-12	E. R. Squibb & Sons, Inc.	Monobactam hydrazide derivatives
US5250691A (en) *	1991-09-09	1993-10-05	E. R. Squibb & Sons, Inc.	Heteroaryl derivatives of monocyclic beta-lactam antibiotics
US5888998A (en) *	1997-04-24	1999-03-30	Synphar Laboratories, Inc.	2-oxo-1-azetidine sulfonic acid derivatives as potent β-lactamase inhibitors
US5994340A (en)	1997-08-29	1999-11-30	Synphar Laboratories, Inc.	Azetidinone derivatives as β-lactamase inhibitors

2001
- 2001-09-14 WO PCT/IB2001/002115 patent/WO2002022613A1/en not_active Ceased
- 2001-09-14 AT AT01980829T patent/ATE298750T1/de active
- 2001-09-14 EP EP01980829A patent/EP1322648B1/de not_active Expired - Lifetime
- 2001-09-14 CZ CZ2003-606A patent/CZ304586B6/cs not_active IP Right Cessation
- 2001-09-14 PL PL360537A patent/PL218196B1/pl unknown
- 2001-09-14 AU AU2002212614A patent/AU2002212614B2/en not_active Ceased
- 2001-09-14 DE DE60111757T patent/DE60111757T2/de not_active Expired - Lifetime
- 2001-09-14 CA CA2422375A patent/CA2422375C/en not_active Expired - Fee Related
- 2001-09-14 BR BR0113861-8A patent/BR0113861A/pt active Search and Examination
- 2001-09-14 IL IL15459301A patent/IL154593A0/xx active IP Right Grant
- 2001-09-14 JP JP2002526866A patent/JP2004509122A/ja active Pending
- 2001-09-14 DK DK01980829T patent/DK1322648T3/da active
- 2001-09-14 CN CNB018157319A patent/CN1189469C/zh not_active Expired - Fee Related
- 2001-09-14 SK SK246-2003A patent/SK2462003A3/sk unknown
- 2001-09-14 HU HU0301025A patent/HUP0301025A3/hu unknown
- 2001-09-14 KR KR1020037003718A patent/KR100854810B1/ko not_active Expired - Fee Related
- 2001-09-14 AU AU1261402A patent/AU1261402A/xx active Pending
- 2001-09-14 PT PT01980829T patent/PT1322648E/pt unknown
- 2001-09-14 ES ES01980829T patent/ES2244666T3/es not_active Expired - Lifetime
- 2001-09-14 NZ NZ524292A patent/NZ524292A/en unknown
- 2001-09-14 ZA ZA200302085A patent/ZA200302085B/en unknown
- 2001-09-14 US US10/363,222 patent/US6916803B2/en not_active Expired - Fee Related
2003
- 2003-02-24 IL IL154593A patent/IL154593A/en not_active IP Right Cessation
- 2003-03-13 NO NO20031162A patent/NO324946B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
CN1458932A (zh)	2003-11-26
ZA200302085B (en)	2004-03-15
PL218196B1 (pl)	2014-10-31
ATE298750T1 (de)	2005-07-15
HUP0301025A2 (hu)	2004-04-28
CA2422375A1 (en)	2002-03-21
NO20031162D0 (no)	2003-03-13
KR100854810B1 (ko)	2008-08-27
HUP0301025A3 (en)	2009-03-30
US6916803B2 (en)	2005-07-12
KR20030039369A (ko)	2003-05-17
IL154593A0 (en)	2003-09-17
DE60111757D1 (de)	2005-08-04
CA2422375C (en)	2011-03-15
CN1189469C (zh)	2005-02-16
AU2002212614B2 (en)	2006-12-07
EP1322648B1 (de)	2005-06-29
DK1322648T3 (da)	2005-10-31
CZ2003606A3 (cs)	2003-08-13
JP2004509122A (ja)	2004-03-25
HK1054377A1 (en)	2003-11-28
PL360537A1 (en)	2004-09-06
SK2462003A3 (en)	2003-09-11
ES2244666T3 (es)	2005-12-16
NZ524292A (en)	2004-09-24
AU1261402A (en)	2002-03-26
US20040019203A1 (en)	2004-01-29
WO2002022613A1 (en)	2002-03-21
BR0113861A (pt)	2004-01-27
DE60111757T2 (de)	2006-04-27
EP1322648A1 (de)	2003-07-02
PT1322648E (pt)	2005-11-30
IL154593A (en)	2008-06-05
NO20031162L (no)	2003-03-13
CZ304586B6 (cs)	2014-07-23

Legal Events

Date	Code	Title	Description
2012-04-30	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
US6916803B2 (en)	2005-07-12	3-(Heteroaryl acetamido)-2-oxo-azetidine-1-sulfonic acids derivatives as antibacterial agents
AU2002212614A1 (en)	2002-06-13	3-(heteroaryl acetamido)-2-oxo-azetidine-1-sulfonic acids derivatives as antibacterial agents
EP0893446B1 (de)	2006-10-04	Cephemverbindungen und medikamente die diese verbindungen enthalten
DK159156B (da)	1990-09-10	Analogifremgangsmaade til fremstilling af (2-(2-aminothiazol-4-yl)-2-(0-substitueret)-oxyiminoacetamido)-7-cephalosporan-syre og fysiologisk acceptable salte deraf
RU2183212C2 (ru)	2002-06-10	Антибактериальные цефалоспорины, фармацевтическая композиция на их основе и способ лечения
KR870000826B1 (ko)	1987-04-23	세팔로스포린 유도체의 제조방법
EP0266896B1 (de)	1992-08-05	7-[(Meta-substituiert)-phenylglycin]-1-carba-1-dethia-cephalosporine
NO152654B (no)	1985-07-22	Analogifremgangsmaate ved fremstilling av nye, terapeutisk aktive derivater av 7-acylamido-3-cephem-4-karboksylsyre
NO802686L (no)	1978-10-24	Fremgangsmaate for fremstilling av en ester av et klavulansyreamin
EP0949262B1 (de)	2001-08-22	Cephemderivate
JPH0460476B2 (de)	1992-09-28
KR20220061163A (ko)	2022-05-12	사이드로포어 세팔로스포린 접합체 및 이의 용도
US4103011A (en)	1978-07-25	Novel penicillin compounds and process for preparation thereof
KR20040000380A (ko)	2004-01-03	항균성 치환7-아실아미노-3-(메틸히드라조노)메틸-세팔로스포린 및중간체
HK1054377B (en)	2006-02-03	3-(heteroaryl acetamido)-2-oxo-azetidine-1-sulfonic acids derivatives as antibacterial agents
US4808579A (en)	1989-02-28	Novel monocycle β-lactam antibacterials
US4201781A (en)	1980-05-06	Substituted 7[s-oxopyrido[2,3-d]pyrimidine carboxamido acetamido]cephalosporins
Gérardin et al.	1995	Synthesis of potential γ-lactam antibiotics
HU187574B (en)	1986-01-28	Process for producing antibacterial 6-comma above-square bracket-2-amino-2-bracket-4-acyl-oxy-phenyl-bracket closed-acetamido-square bracket closed-pename-3-carbonyl-oxy-methyl-pename-3-carboxylate-1,1-dioxide compounds
JPH07196660A (ja)	1995-08-01	２−（ヘテロシクロアルケニルアルキル）チオカルバペネム誘導体
HU191661B (en)	1987-03-30	Process for preparing 7beta-acylamido-3-cefem-4-carboxylic acid derivatives and pharmaceutical preparations comprising the same as active substance
EP1090920A1 (de)	2001-04-11	Cephem-derivate
KR19980076908A (ko)	1998-11-16	세팔로스포린 화합물 및 그 제조방법
HU180307B (en)	1983-02-28	Process for producing new 7-beta-square bracket bracket-2,3-dioxo-1-piperazine-carboxamido-aracket closed-hydroxy-amido-square bracket closed-7-alpha-metoxy -ceph-3-eme-4-carboxylic acid derivatives